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Abstract
It is well known that cytokinins are a class of phytohormones that promote cell division in plant roots and shoots. However,
their targets, biological functions, and implications in mammalian systems have rarely been examined. In this study, we
show that one cytokinin, zeatin riboside, can prevent pheochromocytoma (PC12) cells from serum deprivation-induced
apoptosis by acting on the adenosine A2A receptor (A2A-R), which was blocked by an A2A-R antagonist and a protein kinase
A (PKA) inhibitor, demonstrating the functional ability of zeatin riboside by mediating through A2A-R signaling event. Since
the A2A-R was implicated as a therapeutic target in treating Huntington’s disease (HD), a cellular model of HD was applied
by transfecting mutant huntingtin in PC12 cells. By using filter retardation assay and confocal microscopy we found that
zeatin riboside reversed mutant huntingtin (Htt)-induced protein aggregations and proteasome deactivation through A2A-R
signaling. PKA inhibitor blocked zeatin riboside-induced suppression of mutant Htt aggregations. In addition, PKA activated
proteasome activity and reduced mutant Htt protein aggregations. However, a proteasome inhibitor blocked both zeatin
riboside-and PKA activator-mediated suppression of mutant Htt aggregations, confirming mediation of the A2A-R/PKA/
proteasome pathway. Taken together, zeatin riboside might have therapeutic potential as a novel neuroprotectant and a
lead for treating neurodegenerative disorders.
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Introduction
Cytokinins are plant hormones that play essential roles in
regulating various aspects of plant growth and development, such
as de novo bud formation, release of buds from apical dominance,
leaf expansion, chloroplast formation, delay of senescence,
promotion of seed germination, and control of the cell cycle
[1,2]. Naturally occurring cytokinins are mainly adenine deriva-
tives, such as isopentyladenine and trans-zeatin, and synthetic
cytokinins include some adenine analogues, such as 6-benzylade-
nine and kinetin. In plants, the cytokinin signaling pathway is
similar to bacterial and yeast two-component signal transduction
pathways; it is specifically similar to histidine-aspartate multi-step
phosphorelays, which are comprised of sensor kinases, histidine
phosphotransfer proteins, and response regulators [3]. In animal
cells, cytokinins are also of interest for their antioxidative,
antitumorigenic, and anti-aging activities [4–7].
Previously, cytokinin-binding proteins were found in mamma-
lian sera [8], demonstrating the existence of mammalian targeting
proteins for plant hormones. Later, Froldi et al. [9] showed that 6-
benzyladenine could act on a purinergic type-2 receptor that
induces calcium mobilization in rat atria, suggesting a membrane-
bound protein for cytokinins in animal cells. In addition, since
cytokinins are important at specific phases of the plant cell cycle
[10], in parallel, their anticancer effects were attributed to
mediation by cyclins [11] or cyclin-dependent kinases [12,13],
suggesting the potential for cytokinins as anticancer drugs [7].
Thus, cytokinin might be used as a plant hormone and also could
possibly serve as a candidate for treating human diseases.
However, most of the targeting sites and mechanisms are still
mostly unknown.
On the other hand, purinoreceptors can be subdivided into
P1 receptors, which bind adenosine as a natural ligand, and P2
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38865receptors, which bind ATP, ADP, and adenine dinucleotides,
but also pyrimidines like UTP and UDP [14]. On the basis of
cloning, pharmacology, and transduction mechanisms, the P1
receptor family is divided into four subtypes (A1,A 2A,A 2B, and
A3), while the P2 receptor family is divided into P2X ionotropic
receptors (P2X1–7) and P2Y metabotropic G protein-coupled
receptors (P2Y1, 2, 4, 6, and 11–14) [15]. These receptors are
involved in regulating health and disease [16], including
neuroprotection and neurodegeneration [17–20], such as ische-
mia, epilepsy, depression, Alzheimer’s disease (AD), Parkinson’s
disease (PD), and Huntington’s disease (HD). Therefore, due to
the close connections of these purinoreceptors in regulating
diverse physiological and pathological neuronal functions, recent
advances in therapies using purinergic-related drugs in a wide
range of pathological conditions have occurred [18,21–23]. In
addition, 6-benzyladenine can act on the P2 receptor [9], and
almost all cytokinins are present in plants as both a free base
and corresponding nucleosides and nucleotides [24] which have
similar adenosine-based structures as agonists of P1 receptors.
We thus questioned if cytokinins (with or without ribosides) can
act on P1 receptors. Among them, the adenosine A2A receptor
(A2A-R) has drawn attention as a potential therapeutic drug
target in HD because it is highly prevalent in the striatum
where mutant huntingtin (Htt) causes selective neural cell loss
and atrophy. Therefore, A2A-R-related drugs were suggested for
treating HD [25,26].
HD is an autosomal dominant neurodegenerative disorder
caused by the expansion of a glutamine repeat in the Htt with a
distinct phenotype characterized by chorea, dystonia, incoordi-
nation, cognitive decline, and behavioral difficulties [27].
Mutant Htt results from a CAG trinucleotide expansion in
exon 1 leading to an expanded polyglutamine (polyQ) strand at
the N terminus and a putative toxic gain of function. Normally,
the Htt gene has 35 or fewer CAG repeats in its N-terminal
region, whereas that of HD patients is associated with 36 or
more repeats. The numbers of CAG repeats is negatively
correlated with the onset age of HD [28]. During disease
progression, concentration and short-term memory diminish,
and involuntary movements of the head, trunk, and limbs
increase. Finally, death results from complications such as
choking, infection, and heart failure. Currently, therapeutic
strategies for treating HD patients are mostly for symptom
relief, and some treatments have unfavorable side effects [29].
Therapeutic drugs to treat HD are urgently needed to be
developed.
Collectively, in this study, we found that cytokinin can act on
the A2A-R and prevent mutant Htt aggregations suggesting that
cytokinin could possibly be applied as a lead or a novel
neuroprotectant for treating neurodegenerative disorders.
Results
Zeatin Riboside Activates the A2A-R Signaling and
Prevents Serum Deprivation-induced Apoptosis
Kinetin riboside and zeatin riboside, but not kinetin, zeatin,
or N
6-benzyladenine, significantly prevented serum deprivation-
induced cell death (Fig. 1A). As the positive controls, NGF
(Fig. 1A) and CGS 21680 (CGS; a commercially available A2A-
R agonist) also prevented serum deprivation-induced cell death
(Fig. 1B) [30]. Since zeatin riboside at 100 mM exerted the
highest protection with the exception of that by kinetin riboside,
100 mM zeatin riboside was used throughout the following
experiments. Zeatin riboside also reversed H2O2–induced cell
death (Fig. 1A). Pharmacologically, two commercially available
A2A-R-specific antagonists [ZM 241385 (ZM) and SCH 58218
(SCH)] and a PKA inhibitor (H-89) dose-dependently blocked
the protection by zeatin riboside (Fig. 1B). The blockade of
zeatin riboside protection by ZM was re-confirmed by trypan
blue exclusion assay (Fig. 1B). In addition, zeatin riboside
prevented serum deprivation-induced increased fluorescence of
Annexin V-FITC (a marker of apoptotic events) (Fig. 1C). As
expected, ZM and SCH blocked the protective effect of zeatin
riboside as revealed by imaging (Fig. 1C, upper panels) and flow
cytometry studies (Fig. 1C, lower panels). Further, during the
differential time course of serum deprivation, zeatin riboside
significantly attenuated serum deprivation-induced cleavage of
poly (ADP-ribose) polymerase (PARP) and caspase-3 at 24 h
(Fig. 1D).
Zeatin Riboside Targets the A2A-R and Decreases Mutant
Htt Aggregations which Impair Proteasome Activity
The filter retardation assay and confocal microscopic study
revealed that zeatin riboside significantly decreased mutant Htt
(109Q) aggregations (Fig. 2A–C). CGS also prevented mutant Htt
aggregations (Fig. 2A). However, in the absence and presence of
zeatin riboside treatment, normal Htt (25Q) failed to induce any
significant aggregations (Fig. 2A–C). ZM or H-89 pretreatment
significantly reversed the zeatin riboside-induced decrease in
mutant Htt aggregations (Fig. 2B–D). Alternatively, as revealed by
contransfection with pZsProsensor, mutant Htt, but not normal
Htt, resulted in an increased intensity of green fluorescent proteins
(GFPs) (Fig. 2D). Zeatin riboside significantly blocked this
phenomenon, which was also reversed by ZM pretreatment
(Fig. 2D).
Inhibition of Proteasome Exacerbates Htt Aggregations
MG 132, a proteasome inhibitor, significantly induced intense
green fluorescence in normal Htt-overexpressed cells (Fig. 3A). In
addition, MG 132 exacerbated mutant Htt-induced protein
aggregations and reversed zeatin riboside-induced suppression of
Htt aggregations (Fig. 3A and 3B). Compared to Htt-25Q
overexpression, that of Htt-109Q significantly reduced proteasome
activity (Fig. 3C). MG 132 drastically inhibited proteasome activity
in both Htt-25Q- and Htt-109Q-overexpressing cells (Fig. 3C).
ZM significantly attenuated zeatin riboside-induced increased
proteasome activity in both Htt-25Q- and Htt-109Q-overexpress-
ing cells (Fig. 3C).
Activation of PKA Results in a Decrease in Mutant Htt
Aggregations
Forskolin (FK) and dibutyl-cyclic AMP (db-cAMP) (two
known PKA activators) significantly attenuated mutant Htt-
induced protein aggregations, while H-89 reversed this phe-
nomenon (Fig. 4A, B). In addition, FK also blocked mutant
Htt-induced increases in GFPs (Fig. 4B). H-89 blocked this
phenomenon afforded by FK (Fig. 4B). MG 132 not only
blocked the protection by FK but also exacerbated Htt
aggregations in both 25Q- and 109Q-overexpressing cells
(Fig. 4B). FK had no effect on normal Htt or GFP expressions
(Fig. 4B). FK significantly increased proteasome activity in both
normal and mutant Htt-overexpressed cells; however, H-89
pretreatment blocked the effects of FK (Fig. 4C). Additionally,
overexpression of mutant Htt decreased proteasome activity
(Fig. 4C). In addition, FK and zeatin riboside significantly
increased the ratio of YFP/CFP in AKAR1-transfected cells;
however, H-89 pretreatment blocked the effects of both FK and
zeatin riboside (Fig. 4D).
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38865Figure 1. Cytokinins acting on the A2A-R prevent serum deprivation-induced PC12 cell apoptosis. (A) Serum-contained and serum-
deprived cells were treated with or without the indicated reagent(s) for 24 h. NGF were treated in 100 ng/ml. Besides, cells pretreated with zeatin
riboside (100 mM) for 3 h were treated with or without H2O2 (25 mM) for 24 h. Cell viability was expressed as a percentage of the results from the MTT
assay with respect to the mean value of the serum-contained control group. Data points represent the mean 6 SEM (n=3,6). *p,0.05, compared to
its serum-deprived group. #p,0.05, compared to the H2O2-treated group. (B) Serum-deprived cells were pretreated with or without the indicated
reagents for 30 min. Zeatin riboside or CGS (0.1 mM) was added for another 24 h. Cell viability was expressed as a percentage of the results from the
MTT and trypan blue exclusion assays with respect to the mean value of the serum-contained control group. Data points represent the mean 6 SEM
(n=3,6). *p,0.05, compared to its serum-deprived group. (C) Serum-deprived cells were pretreated with or without 1 mMZ Mo r1mM SCH for
30 min. Zeatin riboside was added for 24 h and followed by Annexin V-FITC staining. Cells were subjected to image and cytometry analysis. Bar
represents 50 mm. Data points represent the mean 6 SEM (n=3,6). *p,0.05, compared to the serum-contained control group. (D) Serum-contained
or -deprived cells in the presence or absence of zeatin riboside were harvested and subjected to a Western blot analysis. The relative optical density
of the bands were quantified by densitometry relative to actin and normalized to the levels in serum-contained control group or in serum-deprived
for 24 h group. Data points (mean 6 SEM) represent one out of three independent experiments that gave similar results. *p,0.05, compared to its
serum-containing control group. #p,0.05, compared to its 24 h serum-deprived group. AU represents arbitrary unit.
doi:10.1371/journal.pone.0038865.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38865Figure 2. Zeatin riboside acting on the A2A-R attenuates mutant Htt aggregations. (A) pHtt-25Q-mKate- or pHtt-109Q-mKate-transfected
cells were treated with 1 mM CGS or zeatin riboside for 24 h. Cells were harvested and subjected to a filter retardation assay and Western blot
analysis. (B) The transfected cells were pretreated with or without 1 mM ZM for 30 min and treated with zeatin riboside for another 24 h. Cells were
harvested and subjected to a filter retardation assay and Western blot analysis. (C) The transfected cells were pretreated with or without 5 mM H-89
for 30 min and treated with zeatin riboside for another 24 h. Cells were harvested and subjected to a filter retardation assay and Western blot
analysis. The relative optical density of the bands (A,C) were quantified by densitometry relative to actin and normalized to the levels under the Htt-
109Q-overexpressed control condition. Data points represent the mean 6 SEM. *p,0.05, compared to the mutant Htt control group. #p,0.05,
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Zeatin Riboside Mediates the A2A-R Signalings and
Prevents Serum Deprivation-induced Apoptosis
According to our recently published pharmacophore models of
the A2A-R [31], the Ki of some cytokinins were ranged from 2.9 to
46 mM (Supplement S1). We next tested their biological functions
using a serum deprivation-induced cell death model that
highlighted the functional role of the A2A-R [30]. Among these
cytokinins, only kinetin and zeatin with riboside were protective in
this model (Fig. 1A). The inabilities of other cytokinins in
preventing cell death were not clear. Further works were required
to be done to reveal if they could act as antagonists. The
protection by zeatin riboside was blocked by two A2A-R
antagonists, ZM and SCH (Fig. 1B), indicating an A2A-R-
mediated effect. The protections of NGF and CGS (Fig. 1A–B)
were also consisted with the previously published article [30].
Besides, except serum deprivation-induced cell death, zeatin
riboside also prevented H2O2-induced cell death (Fig. 1A), further
confirming the protections of zeatin riboside. Annexin V-FITC
staining confirmed that ZM and SCH could block the protection
by zeatin riboside in antagonizing serum deprivation-induced
apoptosis (Fig. 1C). A time course study of serum deprivation-
induced cleavage of PARP and caspase 3 which was blocked by
zeatin riboside (Fig. 1D) also confirmed that serum deprivation
induces apoptosis [30]. Furthermore, the above identified protec-
tants (CGS and NGF) and other known protectants (db-cAMP and
FK) [30] were also confirmed to prevent serum deprivation-
induced cleavage of PARP (Supplement S2). Although serum
deprivation-induced apoptosis is well documented, there are still
different forms of death events should be concerned, for instance,
serum deprivation-induced autophagic cell death [32,33] or a new
form of death (parthanatos) which is triggered by the nuclear
translocation of mitochondrial apoptosis inducing factor resulting
in caspase-independent cell death [34]. Thus, the involvement of
zeatin riboside in antagonizing other form of cell death is currently
unknown and requires further investigation.
Normally, signaling of the A2A-R sequentially couples with GSa
and involves activation of adenylyl cyclase, formation of cAMP,
stimulation of PKA, and phosphorylation activation of the CREB
at Ser133 [30,35,36], which plays a pivotal role in neuronal
survival [37] and genetic models of HD [38]. We further
examined and found that zeatin riboside did induce CREB
phosphorylation which could also be blocked by ZM and H-89
(Supplement S3A). Besides, CREB overexpression blocked mutant
Htt aggregations (Supplement S3B) may further confirm the
importance of A2A-R signalings in this system. Therefore, since the
A2A-R has implicated as a therapeutic target in treating HD
[25,26,39], we thus tested if zeatin riboside could be a candidate to
treat HD.
Zeatin Riboside Targets the A2A-R and Decreases Mutant
Htt Aggregations that Impair Proteasome Activity
In order to study HD outside of animal models, several cell
models were established and examined [40,41]. In this study,
plasmid which harbors the exon 1 region of the Htt gene with 25
or 109 CAG repeats conjugating with the red fluorescent protein
(mKate) as a reporter were transiently transfected (Supplement
S4). The filter assay revealed that zeatin riboside dose-dependently
attenuated mutant Htt aggregations (Fig. 2A). CGS also prevented
Htt aggregates in this system (Fig. 2A), consistent with previous
findings [26]. Further, ZM (Fig 2B) and H-89 (Fig. 2C) attenuated
zeatin riboside-induced suppression of mutant Htt aggregations,
demonstrating that zeatin riboside targets the A2A-R and the
subsequent PKA to prevent mutant Htt aggregations. Alterna-
tively, the imaging study revealed that 109Q, not 25Q, induced
highly condensed and punctuated red and green fluorescent
proteins (Fig. 2D), indicating decreased proteasome activity.
However, zeatin riboside alleviated all of these phenomena which
could be reversed by ZM or H-89 pretreatment (Fig.2D),
consistent with the filter assay data. These data indicated that
zeatin riboside by acting on the A2A-R prevents Htt aggregates
and Htt aggregates impair proteasome activity [42,43]. Therefore,
it is possible that zeatin riboside could elevate proteasome activity
to degrade Htt aggregates.
Zeatin Riboside Elevates Proteasome Activity and
Proteasome Inhibition Exacerbates Htt Aggregations
The ubiquitin-proteasome system (UPS) plays an essential role
in degrading misfolded and damaged proteins that are poly-
ubiquitinated by ubiquitin ligases and targeted to proteasomes for
degradation, such as mutant Htt [44]. We thus examined the
importance of proteasomes in degrading Htt aggregates. MG 132,
a proteasome inhibitor, was applied, and found that MG 132
exacerbated Htt aggregations with both 109Q and 25Q (Fig. 3A),
consistent with previous findings [45]. MG 132 also blocked zeatin
riboside-induced suppression of mutant Htt aggregates (Fig. 3A &
3B), confirming the functional role of proteasomes in degrading
Htt aggregates in this system. In addition to the imaging study,
proteasome activity was also detected. Our data revealed that
mutant Htt overexpression downregulated proteasome activity
(Fig. 3C). However, zeatin riboside respectively elevated and
reversed the proteasome activity in normal and mutant Htt-
overexpressed cells. MG 132 drastically inhibited proteasome
activity in normal and mutant Htt-overexpressed cells (Fig. 3C).
Consequently, our data demonstrated that zeatin riboside elevated
proteasome activity and then promoted mutant Htt degradation
by acting on the A2A-R.
PKA Activation Increases Proteasome Activity and Mutant
Htt Degradation
Since PKA is the downstream target of A2A-R, we subsequently
examined if PKA was also involved in mediating Htt aggregates in
this system. Indeed, both FK- and db-cAMP-induced suppression
of mutant Htt aggregates were reversed by H-89 (Fig. 4A), which
indicates a positive role of PKA in suppressing mutant Htt
aggregations. Alternatively, the inhibition by H-89 of FK-induced
suppression of Htt aggregates (Fig. 4B) and the increase in
proteasome activity (Fig. 4C) could also be reproduced using a
confocal study and activity assay, further confirming PKA-
mediated activation of proteasome activity and degradation of
Htt aggregates. Besides, in order to demonstrate whether zeatin
riboside resulted in PKA activation, a genetically encoded reporter
(AKAR1) of PKA activity was used [46]. As expected, H-89
compared to the zeatin riboside-treated mutant Htt group. (D) After 1 mM ZM pretreatment for 30 min, pHtt-25Q-mKate- or pHtt-109Q-mKate-
transfected and pZsProSensor-co-transfected cells were treated with or without zeatin riboside for another 24 h and subjected to a confocal
microscopic analysis. Bar represents 5 mm. In each group, the mKate-aggregated cells in proportion to the transfected cells were counted (100,150
cells) These data points (mean 6 SEM) represent one out of three independent experiments that gave similar results. *p,0.05, compared to the
mutant Htt control group.
doi:10.1371/journal.pone.0038865.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38865Figure 3. Zeatin riboside attenuates mutant Htt aggregations through increasing proteasome activity. (A) With or without 1 mMM G
132 pretreatment for 30 min and following the presence or absence of zeatin riboside for 24 h, pHtt-25Q-mKate- or pHtt-109Q-mKate-transfected
and pZsProSensor-co-transfected cells were subjected to a confocal microscopic analysis. Bar represents 5 mm. In each group, the mKate-aggregated
cells in proportion to the transfected cells were counted (100,150 cells). Data points represent the mean 6 SEM. *p,0.05, compared to the mutant
Htt control group. #p,0.05, compared to the MG 132-treated mutant Htt group. (B) With or without 1 mM MG 132 pretreatment for 30 min, pHtt-
109Q-mKate-transfected cells were treated with or without zeatin riboside for 24 h and subjected to a filter retardation assay and Western blot
analysis. The relative optical density of the bands were quantified by densitometry relative to actin and normalized to the levels under the Htt-109Q-
overexpressed control condition which was set as 1.0. Data points represent the mean 6 SEM. *p,0.05, compared to the mutant Htt control group.
AU represents arbitrary unit. (C) pHtt-25Q-mKate-transfected cells were treated with or without zeatin riboside or 1 mM MG 132. pHtt-109Q-mKate-
transfected cells were pretreated with or without 1 mM ZM for 30 min and then supplemented with or without zeatin riboside or 1 mM MG 132 for
24 h and subjected to a proteasome activity assay. *p,0.05, compared to the Htt-25Q control group. #p,0.05, compared to the Htt-109Q control
group. These data represent one out of three independent experiments that gave similar results.
doi:10.1371/journal.pone.0038865.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38865Figure 4. PKA attenuates mutant Htt aggregations through increasing proteasome activity. (A) With or without 1 mM H-89 pretreatment
for 30 min, pHtt-109Q-mKate-transfected cells were treated with or without 10 mM FK or 100 mM db-cAMP for 24 h and subjected to a filter
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(Fig. 4D), demonstrating that zeatin riboside does mediate PKA.
Therefore, zeatin riboside-induced suppression of Htt aggregations
is mediated by the A2A-R and subsequent PKA-dependent
pathways (Fig. 4E). Currently, the mechanism of mutant Htt-
induced impairment of the UPS is not clear [43,47]; although it
was proposed that polyQ peptides may be transiently retained in
the proteolytic core, thus impairing proteasome activity. However,
it is also possible that mutant Htt aggregates are difficult to
recognize by proteasomes. Further investigations are required to
answer these questions.
Implications of Cytokinins
Recently, biomedical implications of cytokinins have gradually
garnered attention. For instance, kinetin was found to alleviate
some messenger (m)RNA splicing diseases, such as familial
dysautonomia [48]. It was also shown to delay the onset and
decrease the extent of aging characteristics in cultured human skin
fibroblasts [6] and is widely marketed today in a variety of skin-
care products. Although kinetin was reported to protect against
oxidative damage to both DNA and proteins [5,49], the molecular
mechanism for the anti-aging properties is unknown. Since kinetin
is currently used only for topical applications, toxicity studies are
currently underway to assess its potential as a treatment for
familial dysautonomia. On the other hand, zeatin has been found
to prevent scopolamine-induced memory impairment in mice [50]
and b-amyloid-induced PC12 cell neurotoxicity [51], suggesting
the therapeutic potential of cytokinins in treating neurodegener-
ation.
In this study, for the first time, we pharmacologically
demonstrated that zeatin riboside can target the A2A-R to prevent
serum deprivation-induced apoptosis and mutant Htt aggrega-
tions, suggesting a therapeutic potential in treating neuronal injury
and neurodegeneration. In addition, our previously published
articles show that a novel compound, N-(4-hydroxybenzyl)adeno-
sine purified from Gastrodia elata [52], had A2A-R-binding potency
that exerted protection in treating R6/2 mice (an HD animal
model) [53]. This compound may be a novel therapeutic drug and
lead to the development of new drugs to treat other neurodegen-
erative diseases [31]. Therefore, regarding plant hormones,
cytokinins, the application of zeatin riboside or others with A2A-
R-binding affinities may also be possibly implicated as novel
neuroprotectants and leads for alternative treatments of neurode-
generation [25,54].
Taken together, in this study, we showed that zeatin riboside
could prevent serum deprivation-induced apoptosis and mutant
Htt aggregations through activation of the A2A-R and subsequent
PKA-dependent pathways. These findings also indicate the
therapeutic potential of zeatin riboside in treating neuronal injury,
HD, and other polyQ diseases, such as spinocerebellar ataxias.
Materials and Methods
Reagents and Cell Culture
All reagents were purchased from Sigma Chemical (St. Louis,
MO, USA) except where otherwise specified. Nerve growth
factor (NGF) was purchased from Alomone Labs Ltd (Jerusalem,
Israel). 4-[2-[[6-Amino-9-(N-ethyl-b-D-ribofuranuronamidosyl)-
9H-purin-2-yl]amino]ethyl] benzene pro-panoic acid (CGS
21680), 2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]
triazolo[1,5-c]pyrimidin-5-amine (SCH 58261), and 4-(2-[7-ami-
no-2-(2-furyl)[1,2,4] triazolo[2,3-a][1,3,5] triazin-5-ylami-
no]ethyl)phenol (ZM 241385) were purchased from Tocris
(Bristol, UK). H-89 was purchased from Biomol (Plymouth
Meeting, PA, USA). All antibodies were purchased from
Millipore (Bedford, MA, USA) except where otherwise specified.
The anti-PARP antibody was purchase from Epitomics (1078;
Burlingame, CA, USA). The anti-cleaved caspase 3 antibody was
purchase from Cell Signaling (9664; Danvers, MA, USA).
Plasmids including the proteasome sensor vector (pZsProSen-
sor-1) were purchased form Clontech (Mountain View, CA,
USA). Restriction enzymes were purchased from Fermantas
(Vilnius, Lithuania). The AKAR1 plasmid was obtained from Dr.
Roger Y. Tsien (Department of Pharmacology, Department of
Chemistry & Biochemistry, University of California, San Diego,
CA, USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum (FBS), and horse serum were purchased from
HyClone (Logan, UT, USA). Rat PC12 cells purchased from
American Type Culture Collection (ATCC; Manassas, VA,
USA) were maintained in DMEM supplemented with 10% horse
serum and 5% FBS and incubated in a CO2 incubator (5%) at
37uC. pHtt-25Q-mKate and pHtt-109Q-mKate were prepared
as described previously [55].
MTT and Trypan Blue Exclusion Assays
Survival was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) metabolism assay as
described previously [56]. In brief, after treatment, MTT was
added to the medium (0.5 mg/ml) and incubated at 37uC for
2,3 h. The plating number was 10
4 cells/well in a 96-well plate.
After discarding the medium, DMSO was applied to the well to
dissolve the formazan crystals, and the absorbances at 570 and
630 nm in each well were measured on a micro-enzyme-linked
immunosorbent assay (ELISA) reader. In addition, after different
treatments, cells growing on 6-well (4610
5 cells/well) plate were
scraped and counted using a hemacytometer after trypan blue
staining (0.3%).
retardation assay and Western blot analysis. The relative optical density of the bands were quantified by densitometry relative to actin and
normalized to the levels under the Htt-109Q-overexpressed control condition which was set as 1.0. Data points represent the mean 6 SEM. *p,0.05,
compared to the mutant Htt control group. #p,0.05, compared to the FK-treated mutant Htt group. AU represents arbitrary unit. (B) After 5 mMH -
89 or 1 mM MG 132 pretreatment for 30 min, pHtt-25Q-mKate- or pHtt-109Q-mKate-transfected and pZsProSensor-co-transfected cells were treated
with or without 10 mM FK for 24 h and subjected to a confocal microscopic analysis. In each group, the mKate-aggregated cells in proportion to the
transfected cells were counted (100,150 cells). Data points represent the mean 6 SEM. *p,0.05, compared to the mutant Htt control group. (C) With
or without 5 mM H-89 pretreatment for 30 min, pHtt-109Q-mKate-transfected cells were supplemented with or without zeatin riboside or 10 mMF K
for 24 h and subjected to a proteasome activity assay. *p,0.05, compared to the control group.
#p,0.05, compared to the FK-treated but without H-
89-pretreated group. (D) With or without 10 mM H-89 pretreatment for 30 min, AKAR1-transfected cells were added with or without 10 mMF Ko r
zeatin riboside and the FRET images (upper panel) were acquired and analyzed (middle panel). Bar represents 5 mm. In each group, the area under
the curve (AUC) subtracting with the background level was calculated and plotted in arbitrary unit (AU) (lower panel). Data represents the mean 6
SEM (n=3,6). *p,0.05, compared to the control group. (E) Zeatin riboside-mediated suppression of mutant Htt aggregations involves activation of
the adenosine A2A receptor (A2A-R), PKA, and proteasome. Mutant Htt aggregations in turn inhibit proteasome activity. These data represent one out
of three independent experiments that gave similar results.
doi:10.1371/journal.pone.0038865.g004
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Lipofectamine
TM 2000 (Invitrogen) was used as a vehicle to
transfer plasmids into cells as described by the protocol. Normally,
5 mg of DNA combined with 5 ml of Lipofectamine
TM 2000 was
applied to each well of 6-well plates. The plating number was
(1,1.5)610
6 cells/well. After transfections for 6 h, cells were
treated with reagents for another 24 h. Images were then taken
with a Zeiss Axiovert 200 M inverted fluorescence microscope
(Go ¨ttingen, Germany).
Annexin V-FITC Staining and Analysis
An Annexin V (FITC-conjugated) apoptosis kit (K101–400;
BioVision, Mountain View, CA, USA) was used to analyze
apoptotic cells. The experimental protocol followed the manufac-
turer’s instructions. In brief, after a 24-h treatment, cells growing
on 12-well plates at (3,4)610
5 cells/well were loaded with 0.5 ml
binding buffer and 5 ml Annexin V-FITC. After incubation for
5 min in the dark, cells were washed once with 1 ml of culture
medium (without phenol red) to take phase contrast and
fluorescent micrographs. Besides, the stained-cells could also be
used for flow cytometry analysis (FACScanH, Becton Dickinson,
Franklin Lakes, NJ). The mean values of the fluorescent intensities
of FITC were collected using an FL-1 channel (488/530
Ex/
Em nm). Five thousand live cells were analyzed per sample.
Western Blot Analysis
Equal amounts of cell lysates (20 mg/well) derived from the
filtered assay were separated by SDS-polyacrylamide gel electro-
phoresis (PAGE) and then electroblotted onto Immobilon poly-
vinylidene difluoride (PVDF) membranes (Millipore). Membranes
were blocked with 5% skim milk in TBST (100 mM Tris-HC1 and
150 mM NaC1; pH 7.4, containing 0.05% Tween 20) for 1 h at
room temperature and then incubated with the first antibody (1/
1000,2000) at 4uC for overnight. The anti-PARP antibody was
used to probe pro- and cleaved-form of PARP. The anti-caspase 3
(9662; Cell Signaling, Danvers, MA, USA) and anti-cleaved caspase
3 antibodies were respectively used to probe pro- and cleaved-form
of caspase 3. Actin was used as an internal control and probed with
anti-actin (MAB1501) antibody. After three washes with TBST, the
blot was incubated with a second antibody (1:5000) conjugated to
horseradish peroxidase for 1 h, processed for visualization using an
enhanced chemiluminescence system (Pierce, Rockford, IL, USA),
and exposed to Kodak XAR-5 film (Rochester, New York, USA) to
obtain the fluorographic images. The freeware ImageJ (http://
imagej.nih.gov/ij/download.html) was used to measure the re-
quired image density.
Filter Retardation Assay
This method followed that described by Wanker et al. [57] with
a few modifications. In brief, harvested cells were resuspended in
lysis buffer (50 mM Tris-HCl (pH 8.8), 100 mM NaCl,
5.0 mM MgCl2, 1 mM EDTA, and 0.5% (w/v) IPGEAL
containing 16 protease inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN, USA)) and sonicated for 10 s (1 pulse/s). Equal
protein concentrations (15,20 mg/well) in each group were
filtered through a 2% sodium dodecylsulfate (SDS)-pre-equilibrat-
ed cellulose-acetate membrane (0.2 mm; Whatman, Maidstone,
Kent, UK) using the Bio-Dot SF Apparatus (Bio-Rad, Hercules,
CA, USA). During suction, each well was washed with 200 ml
0.1% SDS twice. The blot was blocked in TBS (100 mM Tris-
HC1 and 150 mM NaC1; pH 7.4) containing 3% nonfat dried
milk for 1 h at room temperature and then incubated with the
anti-polyglutamine (1:5000; MAB1574) antibody in 3% bovine
serum albumin (BSA) with 0.02% NaN3 (4uC overnight) to probe
normal and mutant Htts. The subsequent methods were the same
as those described above.
Proteasome Activity Assay
Proteasome activity was indirectly studied by transfecting
pZsProSensor-1 (Clontech), a eukaryotic expression vector de-
signed to express ZsGreen fused to the mouse ornithine
decarboxylase degradation domain which is highly susceptible to
proteasome degradation. Therefore, this vector was used to
monitor proteasome activity in living cells. Normally, if protea-
somes are active in living cells, the protein does not accumulate.
However, when proteasome activity decreases, such as the
addition of a proteasome inhibitor, the fusion protein accumulates
in cells resulting in increased green fluorescence. Therefore,
proteasome activity is inversely correlated with the green
fluorescence. Alternatively, a 20S Proteasome Activity Assay kit
(APT280; Millipore, Billerica, MA, USA) was used to measure the
proteasome activity according to the protocol.
PKA Activity Assay
This method was carried out as described by Zhang et al. [46].
In brief, after AKAR1 transfection for 24 h, cells were imaged on
a Zeiss Axiovert 200 M microscope with a 406/1.3NA oil-
immersion objective lens and a cooled CCD camera (CoolSNAP
HQ
2; Photometrics, Tucson, AZ, USA). Dual-emission ratio
imaging was acquired with a 420DF20 excitation filter, a
450DRLP dichroic mirror, and two emission filters (475DF40
for cyan and 535DF25 for yellow (Chroma Technology, Bellows
Falls, VT, USA)) altered by a filter changer (Lambda DG-4; Sutter
Instruments, San Rafael, CA, USA). Fluorescence images were
background-corrected. Exposure times were 50,200 ms, and
images were taken every 30,60 s.
Confocal Microscopy
Transfected cells growing on poly-L-lysine-coated cover slides
were fixed with 4% paraformaldehyde at room temperature for
10 min, and DAPI (1 mg/ml) stain was applied for another
10 min. After three washes with PBS, cover slides were mounted
onto glass slides with Aqua Poly-Mount (Polysciences, Warrington,
PA, USA). Images of cells were visualized with a Leica TSC SP
confocal laser scanning microscope (Wetzlar, Germany).
Statistical Analysis
Results were analyzed by one- or two-way analysis of variance
(ANOVA) according to which was appropriate. Two-way
ANOVA with repeated measurements were used to analyze the
differences in PKA activity assay. Differences between means were
assessed by the Student-Newman-Keuls method and were
considered significant at p,0.05.
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